Practice Areas

Best Reasonable Efforts to end a global pandemic

Marton Eorsi

Now that the COVID-19 vaccine contract between the EU and AstraZeneca has been published, we take a look at it and the “Best Reasonable Efforts” provisions. The production issues facing the roll-out of the EU vaccination programme have led some to question the centralised approach taken by the European Commission in its procurement of the Read More

The French National Authority for Health proposes the first classification of digital solutions used in healthcare

Alexis Vaujany

Given the growing number of digital tools that can be used in healthcare, the French National Authority for Health (HAS) has recently developed a system for classifying digital healthcare solutions according to their purpose of use, their capacity to provide a personalised response and their autonomy, i.e. their ability to act with or without human Read More

Parallel trade in the life sciences sector – recent developments

Tine Carmeliet

Please join us on Tuesday, 26 January 2021 for a webinar on the key developments in the parallel trade of pharmaceuticals in 2020.  Tine Carmeliet, Nele De Backer, Francesca Miotto, Geert Glas and Nieke Vanavermaete will talk you through recent decisions and developments in the field of parallel trade, review the impact of both Brexit Read More

U.S. – Healthcare accent is on smaller deals

Paul Burns

Transactions in the U.S. healthcare space rebounded in autumn, although with a greater proportion of smaller deals than in recent years. In the year to date, deal value has fallen sharply, but volume has decreased only marginally. Megadeals, common in the sector two or three years ago, are less frequent now. However, we did see Read More

European Commission completes current cycle of pay-for-delay probes with fines imposed on Teva and Cephalon

Thomas Masterman

On 26 November 2020, the European Commission (Commission) issued a decision fining pharmaceutical companies Teva and Cephalon EUR60.5 million for infringing Article 101 TFEU by agreeing to delay the entry of a cheaper generic version of Cephalon’s sleep disorder drug modafinil (the Decision). While the Decision completes the current cycle of the Commission’s “pay-for-delay” investigations, Read More